The enzyme-linked immunosorbent assay market size is estimated to be USD 2,643.7 million in 2021 and is expected to witness a CAGR of 5.76% during the forecast period 2022-2032. The rising occurrence of infectious disorders and increased need for diagnostic technologies that are affordable are factors contributing to the market growth. However, availability of alternative immunoassay methods is expected to hinder the growth.

Segmentation

By Type

Based on type, the market is categorized into indirect ELISA, sandwich ELISA, competitive ELISA, and direct ELISA. In 2021, the indirect ELISA accounted for the highest revenue share due to the more cost-effective than other ELISA as less labelled antibodies are required.

By Application

On the basis of application, the market is categorized into immunology, diagnostics, vaccine development, drug monitoring & pharmaceuticals, toxicology, and transplantation. In the global market, the diagnostics segment accounted for the largest revenue share in 2021 owing to the increased prevalence of infectious disorders.

By End User

Based on end user, the market is segmented into research laboratories, hospital & diagnostic centres, and others. In 2021, the hospital & diagnostic centres segment accounted for the largest revenue share owing to increasing number of patients visiting hospitals and diagnostic facilities.

Regional Markets

In 2021, North America region accounted for the highest revenue in the enzyme-linked immunosorbent assay market and is expected to maintain its dominance during the forecast period. This is attributed to the expanding technical improvements and increasing prevalence of infectious disorders.

Competitor Insights

Some of the key players operating in the enzyme-linked immunosorbent assay market are AESKU.GROUP GmbH & Co. KG (Germany), Sysmex Corporation (Japan), PerkinElmer Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux (France), R&D Systems, Inc. (U.S.), Eurofins Scientific (Luxembourg), Biogenuix (India), F. Hoffmann-La Roche Ltd (Switzerland), RayBiotech Life Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Abbott (U.S.), Danaher (U.S.), BD (U.S.), Merck KGaA (Germany), and Agilent Technologies Inc. (U.S.).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type, application, and end user from 2021 to 2032.

Report Scope:

Segmentation: Enzyme-Linked Immunosorbent Assay Market Report 2021- 2032

Type (Revenue, USD Million)

• Indirect ELISA
• Sandwich ELISA
• Competitive ELISA
• Direct ELISA

Application (Revenue, USD Million)

• Immunology
• Diagnostics
• Vaccine Development
• Drug Monitoring & Pharmaceuticals
• Toxicology
• Transplantation

End user (Revenue, USD Million)

• Research Laboratories
• Hospital & Diagnostic Centres
• Others

End user (Revenue, USD Million)

• Homecare
• Ambulatory Surgical Centres
• Hospitals

By Region (Revenue, USD Million)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA